Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3705558 | 0.79 | DCPS (0.47) | HSD17B10ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL14213484 | 0.79 | CYP2A6 (0.33) | ALDH1A1 | |
| SCHEMBL12643902 | 0.76 | ADORA2A (0.38) | HSD17B10ALDH1A1CYP1A2HPGDNUDT1 | |
| SCHEMBL7607941 | 0.76 | KDM4E (0.35) | ALDH1A1MAPT | |
| SCHEMBL22161609 | 0.76 | CYP2A6 (0.31) | — | |
| SCHEMBL18211812 | 0.73 | AURKA (0.32) | ALDH1A1ADORA2AMAPT | |
| SCHEMBL21341741 | 0.73 | ALDH1A1 (0.31) | ALDH1A1ADORA2ATP53MAPT | |
| SCHEMBL18924353 | 0.73 | PDE4A (0.39) | HSD17B10ALDH1A1ADORA2AMAPT | |
| SCHEMBL16840458 | 0.73 | NUDT1 (0.39) | HSD17B10CYP1A2NUDT1ADORA2A | |
| SCHEMBL13169635 | 0.72 | GPR3 (0.55) | HSD17B10ALDH1A1CYP1A2HPGDNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083560-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | HSD17B10 2078/4885ALDH1A1 1671/4885CYP1A2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.